key: cord-0305565-7nvuyt5z
authors: Tu, Joshua J; Kumar, Amit; Giorgi, Elena E; Eudailey, Josh; LaBranche, Celia C; Martinez, David R; Fouda, Genevieve G; Moreau, Yvetane; Thomas, Allison; Montefiori, David; Gao, Feng; Sagar, Manish; Permar, Sallie R
title: Vertical HIV-1 transmission in the setting of maternal broad and potent antibody responses
date: 2022-02-08
journal: bioRxiv
DOI: 10.1101/2022.02.03.479075
sha: 18c60cbd5193b080994b317812de86e74020b3fa
doc_id: 305565
cord_uid: 7nvuyt5z

Despite the worldwide availability of antiretroviral therapy (ART), approximately 150,000 pediatric HIV infections continue to occur annually. ART can dramatically reduce HIV mother-to-child transmission (MTCT), but inconsistent drug access and adherence, as well as primary maternal HIV infection during pregnancy and lactation are major barriers to eliminating vertical HIV transmission. Thus, immunologic strategies to prevent MTCT, such as an HIV vaccine, will be required to attain an HIV-free generation. A primary goal of HIV vaccine research has been to elicit broadly neutralizing antibodies (bnAbs) given the ability of passive bnAb immunization to protect against sensitive strains, yet we previously observed that HIV-transmitting mothers have more plasma neutralization breadth than non-transmitting mothers. Additionally, we have identified infant transmitted/founder (T/F) viruses that escape maternal bnAb responses. In this study, we examine a cohort of postpartum HIV-transmitting women with neutralization breadth to determine if certain maternal bnAb specificities drive the selection of infant T/F viruses. Using HIV pseudoviruses that are resistant to neutralizing antibodies targeting common bnAb epitopes, we mapped the plasma bnAb specificities of this cohort. Significantly more transmitting women with plasma bnAb activity had a mappable plasma bnAb specificity (six of seven, or 85.7%), compared to that of non-transmitting women with plasma bnAb activity (seven of twenty-one, or 33.3%, p=0.029 by 2-sided Fisher exact test). Our study suggests that having multispecific broad activity and/or uncommon epitope-specific bnAbs in plasma may be associated with protection against the vertical HIV transmission in the setting of maternal bnAb responses. Importance As mother to child transmission (MTCT) of HIV plays a major part in the persistence of the HIV/AIDS epidemic and bnAb-based passive and active vaccines are a primary strategy for HIV prevention, research in this field is of great importance. While previous MTCT research has investigated the neutralizing antibody activity of HIV-infected women, this is to our knowledge the largest study identifying differences in bnAb specificity of maternal plasma between transmitting and non-transmitting women. Here, we show that among HIV-infected women with broad and potent neutralization activity, more postpartum-transmitting women had a mappable plasma broadly neutralizing antibody (bnAb) specificity, compared to that of non-transmitting women, suggesting that the non-transmitting women more often have multi-specific bnAb responses or bnAb responses that target uncommon epitopes. Such responses may be required for protection against vertical HIV transmission in the setting of maternal bnAb responses.

Despite the worldwide availability of antiretroviral therapy (ART), approximately 150,000 24 pediatric HIV infections continue to occur annually. ART can dramatically reduce HIV mother-to-25 child transmission (MTCT), but inconsistent drug access and adherence, as well as primary 26 maternal HIV infection during pregnancy and lactation are major barriers to eliminating vertical 27 HIV transmission. Thus, immunologic strategies to prevent MTCT, such as an HIV vaccine, will 28 be required to attain an HIV-free generation. A primary goal of HIV vaccine research has been 29 to elicit broadly neutralizing antibodies (bnAbs) given the ability of passive bnAb immunization to 30 protect against sensitive strains, yet we previously observed that HIV-transmitting mothers have 31 more plasma neutralization breadth than non-transmitting mothers. Additionally, we have 32 identified infant transmitted/founder (T/F) viruses that escape maternal bnAb responses. In this 33 study, we examine a cohort of postpartum HIV-transmitting women with neutralization breadth 34 to determine if certain maternal bnAb specificities drive the selection of infant T/F viruses. Using 35

HIV pseudoviruses that are resistant to neutralizing antibodies targeting common bnAb 36 epitopes, we mapped the plasma bnAb specificities of this cohort. Significantly more 37 transmitting women with plasma bnAb activity had a mappable plasma bnAb specificity (six of 38 seven, or 85.7%), compared to that of non-transmitting women with plasma bnAb activity (seven 39 of twenty-one, or 33.3%, p=0.029 by 2-sided Fisher exact test). Our study suggests that having 40 multispecific broad activity and/or uncommon epitope-specific bnAbs in plasma may be 41 associated with protection against the vertical HIV transmission in the setting of maternal bnAb 42 responses. 43

As mother to child transmission (MTCT) of HIV plays a major part in the persistence of the 45 HIV/AIDS epidemic and bnAb-based passive and active vaccines are a primary strategy for HIV 46 prevention, research in this field is of great importance. While previous MTCT research has 47

Maternal plasma samples collected both prior and closest to the first positive infant HIV test 66 days) from the BAN cohort were previously tested for breadth, and the plasma that 170 neutralized TRO11 and BJOX2000 (2 viruses from the global panel) at an ID50 ≥120 were 171 selected from the available samples (n = 6) (24). To match the transmitting mother sample 172 timepoints, 67 plasma samples collected 4-6 weeks after delivery from mothers from the 173 CHAVI009 cohort who only received peripartum ART were screened for neutralization against 174 11 global panel HIV Env pseudovirus (23, 37, 42, 43) . Broad neutralization activity was defined 175 as plasma neutralization at an ID50 50 for six of the eleven viruses tested. For samples not 176 tested at a dilution of 50 in Figure 2A , we calculated the % neutralization at a dilution of 50 using 177 the mathematical formulation for a single antibody neutralization curve(45). The breadth and 178 potency (BP) score was defined according to equation 1 in . 179

HIV-1 Env pseudoviruses were produced as previously described (46) in 293T cells through co-181 transfection using 4 µg of envelope expression plasmid and 8 µg of backbone plasmid 182 pSG3ΔEnv or pQ23ΔEnv. VSV-G and SVA.MulV viruses were prepared by co-transfection in 183

293T cells with backbone plasmid pNL-LucR-E and pSG3ΔEnv respectively. Virus was 184 harvested after 48 hours post transfection, filtered and stored at -80°C at 20% FBS 185 concentration. Pseudoviruses were tittered by infecting Tzm-bl cells at 5-fold dilutions from 1:10 186 to 1:97,656,250 and the dilution that achieves 50,000 relative luminescence units (RLU) during 187 infection was used in all assays. If the pseudovirus infection did not reach 50,000 RLU, then a 188 dilution that provided an RLU ten times higher than the uninfected cell control was chosen for 189 assays. Maternal amplicons for pseudovirus preparation were selected using a previously used 190 algorithm to represent viral diversity (37). 2315 infant amplicons for pseudovirus preparation 191

were visually selected based on the unique mutations in the known bnAb epitopes (Fig. 5C ). through the NIH HIV Reagent Program, Division of AIDS, NIAID, NIH. Heavy and light chain 195 plasmids were transfected into 293i cells using the Expifectamine kit (ThermoFisher A14524) as 196 per manufacturer guidelines. Transfected cells were incubated for 5 days before harvesting the 197 cell supernatant. Antibodies were purified from culture supernatants using affinity 198 chromatography with protein A beads as previously described (47). After purification, all 199 antibodies were then buffer exchanged into a citric acid buffer (pH 6) before use. 200

VRC01-blocking activity of maternal plasma was detected by competition ELISA method as 202 previously described (41). Briefly, 384 well plates were coated with 45 ng/mL of 1086CK160N 203 gp120 overnight at 4⁰C. 10ul of plasma diluted at 1:30 were added in duplicate and incubated at 204 RT for one hour. Plates were washed twice and 16ng of biotinylated VRC01 was added and 205 incubated at RT for one hour. Plates were washed twice, and HRP-conjugated streptavidin was 206 used at 1:10000 dilution and incubated at RT for one hour. Plates were washed four times and 207 developed using 20μl of SureBlue substrate per well and incubated for 3 minutes and 30 secs. 208

The reaction was stopped using stop solution and the plate was read using a spectrophotometer 209 at 450 nm. Percent blocking was determined by the percent difference in OD (max OD=2.23) 210 between uninhibited bnAb binding and the sample. 50% blocking was defined as the positivity 211

Single Genome Amplification (SGA) 213 SGA sequences were obtained as described previously (37). In brief, RNA was extracted from 214 breast milk and plasma samples and reverse transcribed. The obtained cDNA was used to PCR 215 cDNA to yield no more than 20% PCR positive wells to fit a Poisson distribution of one template 217 per reaction. Autologous env sequences were aligned using Seaview (48) 

Counts of mapped versus non-mapped bNAb specificities were compared between transmitting 231 and non-transmitting mothers using a 2-sided Fisher exact test. Breadth and breadth-potency 232 scores between transmitting and non-transmitting mothers were compared using 2-sided 233

Wilcoxon tests. All tests were run on the R platform (https://www.R-project.org). Heatmaps were 234 created using the Heatmap tool provided on the LANL database 235 (https://www.hiv.lanl.gov/content/sequence/HEATMAP/heatmap_mainpage.html). Phylogenetic 236 trees were created with MEGA-X using a Kimura 2 Parameters (K2P) model (49). 237

Env variable loop lengths, number of glycosylation sites, and net charge were obtained using 238 the LANL tool Variable Region Characteristics 239 (https://www.hiv.lanl.gov/content/sequence/VAR_REG_CHAR/index.html) and compared 240 between mother and infant for ID 2315 using 2-sided Wilcoxon test. Combining the cohorts, we screened a total of 22 transmitting and 106 non-transmitting 254 mothers, for a total size of 128 samples (Fig. 1) . Consistent with previous findings that BAN 255 cohort transmitting mothers had higher neutralizing breadth than non-transmitting mothers 256 (p<0.001)(24), the combined cohort had more transmitting mothers (17/22, or 77%) than non-257 transmitting mothers (42/106, or 40%) that displayed neutralization breadth. 258

In order to explore the specificity of the plasma neutralizing activity in HIV-transmitting and non-259 transmitting women, we selected a subcohort of mothers with comparable breadth and 260 neutralization potency. To this end, we selected plasma samples that had sufficient volume 261 (>140 l) and neutralized at least one virus with an ID50 >120 to facilitate neutralization epitope-262 specificity mapping (Fig. 1 ). This ID50 cut off was chosen based on the ability to observe a three-263 fold reduction in neutralization activity against a bnAb epitope mutant virus measured at a 264 starting plasma dilution of 1:40. Six transmitting and four non-transmitting women from the BAN cohort and one transmitting and 17 non-transmitting women from the CHAVI009 cohort met 266 criteria for the neutralization epitope mapping, yielding a study sample size of seven transmitting 267 and 21 non-transmitting women (Fig 2A, Table 1 ). By design, given how we selected the 268 women, the Breadth Potency Score (BP score, as defined by and the 269 number of viruses neutralized was not different (p=0.12 by Wilcoxon test) among the 270 transmitting and non-transmitting women selected for inclusion in our analysis based on the 271 selection criteria (Fig. 2B) . 272

To identify potential differences in the predominant neutralization epitope specificity in 274 transmitting and non-transmitting women with broad and potent neutralizing plasma responses, 275

we further investigated the specificities of broad neutralization activity in both HIV-transmitting 276 and non-transmitting mothers. Using HIV pseudoviruses that have mutations in epitopes 277 targeted by bnAbs, we sought to map the bnAb specificity of maternal plasma with broad 278 neutralization activity (Fig 3) . The panel included viruses with mutations to the CD4 binding site 279 (N279A or D279N, G458Y, and N276Q), the V2 glycan (N160K), the V3 glycan (N332A), and 280 the membrane-proximal external region (W672A) (see Methods section). We were able to map 281 6 of 7 (85.7%) transmitting women's plasma broad neutralizing activity, two to the N276 CD4 282 binding site (CD4bs), one to the N160 V2 glycan, and two to the N332 V3 glycan. One 283 transmitting mother's broad neutralizing plasma activity was mapped to both the N276 CD4bs 284 and the V3 glycan residue. Of the non-transmitting mothers' plasma, we were able to map 7 of 285 21 (33.3%) that had neutralizing activity. The plasma broad neutralizing activity of four of the 286 non-transmitting mothers was mapped to the N276 CD4bs, while V2 glycan, and V3 glycan 287 regions were mapped for one non-transmitting maternal plasma each. One non-transmitting 288 mother's plasma broad neutralizing activity was also mapped to both the N276 CD4bs and V3 289 glycan epitopes ( Fig 3C) . Yet, for the majority of non-transmitting mothers (n = 14, 66.6%), we 290

were not able to map the plasma broad neutralizing activity to a bnAb epitope, indicating that 291 their plasma neutralizing responses are either multispecific, or alternatively, target an epitope 292 not included in the mutant virus panel. Transmitting mothers in our cohort more frequently had 293 epitope-mappable plasma bnAb specificity that targets at least one of the 4 most common bnAb 294 epitopes (OR=10.9, p=0.029, 2-sided Fisher exact test) compared to non-transmitting women 295 (Fig. 3C) . These results suggest that the plasma HIV-neutralizing breadth among transmitting 296 versus non-transmitting mothers with broad and potent neutralizing activity may be mediated via 297 different antibody specificities. 298

All transmission events studied in this cohort occurred postpartum. As breast milk is known to 300 have lower neutralizing activity than plasma (37) and to be populated by locally-replicating 301 variants (42), thus we sought to determine if bnAb resistance profiles were distinct between 302 breast milk and plasma HIV variants in women with plasma bnAb activity. Autologous viruses 303 from four CHAVI009 mothers, one transmitting and three non-transmitting, with plasma broad 304 neutralizing activity were previously sequenced via single genome amplification (SGA) from 305 plasma and breast milk (37). In transmitting mother 1209, env 1209bmH5 was identified as most 306 similar to the infant 1209 virus population through phylogenetic analysis (Fig. 4) We tested 307 these autologous Env pseudoviruses for bnAb sensitivity against monoclonal antibodies 308 PGT121, PG9, VRC01, and 10E8 ( Fig 5A) . No notable differences in bnAb sensitivity of the milk 309 and plasma viruses were found in the mothers tested. Pseudoviruses prepared using SGAs 310 from both breast milk and plasma of mothers 1209 and 4707 were uniformly resistant to VRC01. 311

Autologous viruses from mother 3305 were uniformly resistant to neutralization against bnAbs 312 PGT121 and PG9. In summary, the neutralization sensitivity profiles of breast milk and plasma-313

isolated Envs appear to be comparable in this cohort.

To explore whether the bnAb resistance of circulating maternal HIV variants could be explained 316 by bnAb activity that was unmappable in the mutant HIV Env pseudovirus assay, we measured 317 VRC01-blocking activity in maternal plasma (Fig. 6 ). All HIV Env pseudoviruses from mothers 318 1209 and 4707 had uniform resistance to VRC01 (Fig. 5) . To determine if VRC01-like antibody 319 binding was present in plasma, we measured VRC01-blocking activity in maternal plasma using 320 a competition ELISA, where percent blocking over 50 percent was considered positive (Fig. 6) . 321

Interestingly, some mothers (129, 1306, 0205, 3507, 2709, 4707) with unmappable plasma 322 bnAb activity by neutralization assay had detectable levels of VRC01 blocking, while plasma of 323 1209, which was mapped to V2 glycan-specific neutralization activity and who postnatally-324 transmitted a VRC01-resistant virus, too had positive VRC01 blocking (68.6% blocking). As 325 expected, autologous HIV Env pseudoviruses from mother 3305 were all sensitive to VRC01 326 and little VRC01 blocking activity was observed in plasma (14.1% blocking). 327

We sought to determine whether viruses transmitted to infants were escape variants of maternal 330 plasma bnAb activity. We analyzed 3 mothers who transmitted virus to their infant, had plasma 331 activity mapped to a defined epitope, and had successful identification of infant virus env 332 sequences (1844i, 2315i, and 1209i). For infant 1209i, the viral population was too diverse to 333 identify an infant T/F virus, so the phylogenetically closest maternal breast milk virus 334 (1209bmH5) was used to represent the infant virus population(37). Phylogenetic tree analysis 335 revealed varying levels of genetic similarity between maternal and infant virus envelopes (Fig.  336   4) . A T/F could not be identified for 1844 and 2315 because of too few infant Envs and 337 extensive diversity among the isolated Envs respectively. Since 1844i and 2315i Envs were genetically different from their maternal counterparts, we chose to focus on these infant 339 sequences for neutralization sensitivity analysis. 340

We addressed whether infant viruses acquired mutations that would lead to 341 neutralization escape from paired maternal plasma bnAbs. While subject 1209's maternal 342 plasma bnAb activity was mapped to the V2 glycan specificity, most of the autologous viruses 343 from this sample, including 1209bmH5, were sensitive to V2 glycan-targeting bnAb PG9 and 344 paired maternal plasma (Fig. 5A) , indicating that this transmission was not related to escape Infant HIV Env pseudovirus 2315g7i was potently neutralized by paired maternal 354 plasma, PG9, and 10E8 but was neutralization resistant to VRC01 and PGT121 (Fig. 5A) . 355

Interestingly, maternal plasma corresponding to infant 2315 was mapped to the N332 V3 glycan 356 specificity and 2315g7i was resistant to corresponding bnAb PGT121 (Fig. 3, Fig. 5A ). We 357 explored this V3 glycan-targeting bnAb resistance of 2315g7i by creating Env pseudovirus 358 mutants 2315g7i.N135K and 2315g7i.T334R. We looked at differences in the V1 and V2 359 regions of 2315 maternal and infant virus envs, as mutations in these regions of the envelope 360 can affect V3-specific bnAb activity (53, 54). These regions in the infant virus envs vary greatly 361 from the maternal variants (Fig. 5C) . Notably, 5 of 8 infant viruses had a K135N mutation which 362 led to the insertion of a putative glycosylation site. Reverting this mutation in 2315g7i.N135K was hypothesized to have increased neutralization resistance to V2 glycan and possibly V3 364 glycan-targeting bnAbs, but the mutant pseudovirus had a similar neutralization profile to the 365 wild-type virus (Fig. 6A) . For the V3 glycan region, all infant envs included the N332 V3 glycan 366 while all maternal env sequences contained mutation T334R which deglycosylates the N332 V3 367 glycan region (Fig. 5C ). We hypothesized that inducing mutation T334R in pseudovirus 2315g7i 368 would increase the Env's neutralization resistance to a larger number of V3 glycan-targeting 369 bnAbs. 2315g7i.T334R still retained neutralization resistance to PGT121 and PGT128 and 370 acquired neutralization resistance to DH427. (Fig. 5B) . However, this mutation also slightly 371 increased neutralization sensitivity to 10-1074 compared to the wild-type pseudovirus (1.96 372 fold). 373

Finally, we compared the length and N-linked glycosylation in the V1V2 and V5 regions 374 as well as the total glycosylation in maternal and corresponding infant envelopes (Fig. 7) , as 375 lengthening and glycosylation in these regions can affect bnAb neutralization sensitivity (53-55). 376

Interestingly, infant 2315i env sequences had significantly higher glycosylation sites in the 377 hypervariable V1V2 regions compared to maternal env sequences (p=0.00032 by 2-sided 378

Wilcoxon test) and significantly longer V1V2 hypervariable loops compared to maternal 379 sequences (p=0.0003 by 2-sided Wilcoxon test). Compared to maternal Envs, all 8 infant 380 sequences have insertions 3-11 amino acid long at HXB2 position 188 (Fig. 5C ). While previous 381 studies have found that T/F viruses tend to have shorter V1V2 lengths as it favors transmission 382 fitness(56), longer V1 V2 loops have been associated with resistance to V3 and CD4bs bnAbs 383 (54, 55), consistent with the fact that these viruses are all neutralization resistant to PGT121 and 384 VRC01 (Fig 5A) . This suggests that different transmission fitness pressures could be working on 385 infant T/F viruses in the context of MTCT vertical transmissions. Finally, the net charge of 2315i 386 V1V2 regions were also significantly different than maternal variants. 2315i V1V2 regions 387 tended to be negatively charged while maternal variants were predominantly positively charged (p=0.00044). It has been previously shown that a net positive charge in the V2 strand is 389 correlated with sensitivity to PG9 and PG16 (57), however 2315g7i is phenotypically sensitive to 390 PG9 (Fig. 5A) . In summary, our study is suggestive, yet not definitive on whether infant env 391 mutations are frequently driven by maternal bnAb selection pressure. 392 393

To achieve an HIV-free generation, supplemental strategies in conjunction with ART will be 395 required to prevent MTCT. In this study, we investigated vertical HIV transmission in pregnant 396 women with plasma neutralizing breadth and potency to understand the characteristics of 397 epitope-specific responses that may be protective against virus transmission and/or contribute 398 to selection of transmitted variants during postpartum transmission. Importantly, due to the 399 limited success of the single bnAb prevention approach studied in the Antibody Mediated 400

Prophylaxis (AMP) trial in adults (58), it is clear that understanding transmitted virus escape of 401 bnAb activity is critical to advancing bnAb-based prophylaxis and therapy. The gap in 402 knowledge of protective bnAb combinations for mothers and infants urgently needs addressing, 403 as it will define vaccine strategies and antibody therapies that will be effective in preventing 404

We aimed to define protective bnAb activity in postpartum transmitting and non-406 transmitting mothers from the BAN and CHAVI cohorts by mapping their epitope-specificity 407 using a panel of mutant Env pseudoviruses. We found that more transmitting women had bnAb 408 responses that mapped to 1 or 2 known bnAb specificities compared to non-transmitting 409 women, where the majority were unable to be mapped to common bnAb epitopes, indicating 410 multiple specificities of the neutralization response, responses against undefined epitopes, or 411 responses that were too low to be detected in the pseudovirus neutralization epitope mapping 412 assay. This pattern suggests that multiple bnAb specificities are more common in non-413 transmitting than transmitting women with broad neutralizing activity and may be required to 414 prevent MTCT. Alternatively, this data could also suggest that a currently undefined and 415 infrequent specificity of bnAbs may play a role in prevention of MTCT. 416 We previously demonstrated that autologous HIV viruses isolated from transmitting 417 mothers and their infected infants were enriched with genetic motifs that were associated with 418 resistance to bnAbs (59), suggesting that acquired plasma neutralization-resistance is a 419 common feature of vertically transmitted variants. We also demonstrated that an in utero-420 transmitted virus from a mother with plasma V3 glycan-specific bnAb activity was selected for its 421 ability to escape the mother's dominant bnAb specificity (41). In this study we described a 422 mother-infant transmission pair where the infant envs exhibited V1V2 variable loop 423 characteristics associated with V3 and/or CD4bs bnAb resistance: higher number of 424 glycosylation sites compared to maternal envs, longer V1V2 insertions, and negative net 425 charge. Thus, it is possible that mothers with a single dominant plasma bnAb specificity could 426 drive the selection of resistant viral variants that are in turn, more likely to be transmitted to their 427

infants. An in vitro study using HIV strain BG505 showed that plasma neutralization breadth is 428 moderately correlated to ease of escape via a single mutation (60). Our work demonstrating the 429 potential for lower vertical transmission risk in women with broad, unmappable neutralization 430 activity suggests that transmission may be averted by maternal bnAbs that target uncommon 431 epitopes with a lower capacity for antibody escape via single mutations or with polyclonal bnAb 432 activity. Viruses circulating in women with polyclonal and broad neutralization activity may be 433 less likely to escape bnAbs compared to maternal plasma with a single, dominant specificity, 434 impeding transmission by preventing escape variants. 435

We also tested breast milk and plasma autologous viruses from four mothers for 436 neutralization resistance against bnAbs targeting common bnAb epitopes. We observed no differences in neutralization sensitivities between breast milk and plasma viruses within each 438 mother. This is consistent with a study of 13 subjects from Zambia, which did not find a 439 restriction in viral genotype in breast milk (61) and a previous CHAVI009 study which observed 440 limited compartmentalization of breast milk viruses (62). In this study, several mothers had 441 plasma virus populations with uniform neutralization resistance to some bnAbs. Mothers 1209 442 and 4707 had viruses that were all neutralization resistant to CD4bs-specfic bnAb VRC01. 443

Interestingly, mothers with VRC01-resistant plasma viruses had detectable plasma VRC01-444 blocking activity not identified in the plasma bnAb mapping assay. This could be because 445 binding assays are generally more sensitive than neutralization assays, but as a result we could 446 not confirm these antibodies' function or contribution to the selection of VRC01-resistant 447

We were also able to generate infant HIV Env pseudoviruses for transmitting mother-449 infant pairs with epitope-mapped bnAb responses (1209, 2315, 1844) . We hypothesized that 450 infant HIV Env variants would be resistant to bnAbs targeting the same epitopes as found in the 451 paired maternal plasma. In fact, infant HIV Env variants generated from mother-infant pairs 452 2315 and 1844 were resistant to the maternal mapped specificities, V3 glycan and CD4bs 453 respectively. Despite this, the paired maternal plasma was able to neutralize both infant viruses 454 potently, likely due to other neutralizing antibodies targeting unique specificities present in the 455 plasma. These results suggest that bnAb selection pressure could be driving the transmission of 456 bnAb-resistant viruses, but neutralization resistance may not be required for MTCT. 457

Our study is not without limitations. Our cohort is small due to the sample availability and 458 neutralization activity selection criteria, as bnAb activity is detected in a minority of HIV-infected 459 adults. Additionally, we isolated only a few maternal and infant env variants from the 460 transmitting mother-infant pairs from timepoints late after transmission due to lack of sample 461 availability. Thus, we were not always able to determine if infant-transmitted variants were resistant to paired maternal antibody specificities, as the sequenced virus populations could 463 experience reversions when there is less maternal antibody selection pressure. Another 464 limitation of this study is that we only focused on postpartum transmissions, so observations in 465 this study may not be extrapolated to other modes of MTCT. Future studies should expand our 466 understanding of protective bnAbs by investigating all modes of MTCT, increasing sample size, 467

increasing autologous viruses isolated, and characterizing maternal monoclonal antibodies. 468

Despite our study limitations, this is to our knowledge the largest study identifying differences in 469 bnAb specificity of maternal plasma between transmitting and non-transmitting women. 470

Overall, our results demonstrate that transmitting women with plasma broad neutralizing 471 activity often have antibody activity directed against dominant bnAb epitopes, compared to non-472 transmitting women whose broad neutralizing activity was unable to be mapped to known Transmitting and non-transmitting mothers were screened for plasma neutralization breadth and 501 potency to determine if they had plasma broad neutralizing activity. Mothers with at least 140µl 502 of available plasma and ID50 >120 against at least 1 virus met criteria for this study. 503 Samples not tested at an 1:50 dilution have their % neutralization calculated for said dilution 507 using the mathematical formulation for a single antibody neutralization curve. Colors for % 508 neutralization are described on the color key/histogram. B) Plot of the % of viruses neutralized 509 (x-axis) vs. breadth/potency score (y-axis) for transmitting (red) and non-transmitting (blue) 510 women. The breadth/potency score was not significantly different in between transmitting and 511 non-transmitting women in this cohort. 512 neutralizing activity were tested for bnAb specificities using mutant envelope (Env) 515 pseudoviruses (pseudovirus). Activity was measured by fold change compared to the wild type 516

Env pseudovirus. Colors for fold decrease are described on the color key/histogram. A >2 fold 517 decrease in neutralization compared to the wild type pseudovirus was our positivity threshold. 518 B) ID50s for wild type and mutant pseudoviruses are shown for women with mapped 519 specificities. C) Mapping data is summarized as a pie chart. Significantly more transmitting 520 women were able to be mapped to a bnAb epitope (p=0.029, 2-sided Fisher exact test). 521 CD4bs-specific IgG bnAb, and 10E8 MPER-specific IgG bnAb. Neutralization was measured 530 using ID50 for plasma and IC50 for bnAbs as described in the color keys/histograms. Blood 531 plasma isolated variants are denoted in normal font and Breast milk isolated variants are 532 denoted with "BM" in the name and are in bold. (B) Neutralization sensitivity of 2315g7i 533 autologous pseudovirus and mutants to V3 glycan-specific IgG bnAbs 10-1074, DH427, 534 PGT128, and PGT121. (C) Transmitting mother-infant pair 2315 isolated HIV env sequences had mutations in the V1, V2, and V3 glycan regions that could affect V3 glycan-specific binding. 536 Infant sequences end in "i" and maternal sequences end in "m". The mutations observed were 537 K135N or T, V2 loop extensions at 188, and T334R mutations, respectively as denoted with red 538 arrows and text. 539 

UNAIDS. Global HIV & AIDS statistics -2021 Fact sheet

HIV 552 Care Experiences During the COVID-19 Pandemic: Mixed-Methods Telephone Interviews with Clinic-553 Enrolled HIV-Infected Adults in Uganda

Mother-to-child transmission of human immunodeficiency virus type 1

HIV: prevention of mother-to-child transmission

Selective 559 transmission of human immunodeficiency virus type-1 variants from mothers to infants

Virus Type-1 Envelope V3 Region Isolates from Mothers and Infants after Perinatal Transmission

Perinatal transmission of major, minor, and 565 multiple maternal human immunodeficiency virus type 1 variants in utero and intrapartum

Neutralizing antibodies and viral 568 characteristics in mother-to-child transmission of HIV-1

Phylogenetic and phenotypic analysis of 570 HIV type 1 env gp120 in cases of subtype C mother-to-child transmission

subtype C envelope glycoprotein from perinatally infected Zambian infants

Broadly neutralizing 575 antibody-mediated protection of macaques against repeated intravenous exposures to simian-human 576 immunodeficiency virus

Sustained Delivery of a 578 Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against 579

Simian/Human Immunodeficiency Virus Infection

Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates from Mucosal 582

Simian-Human Immunodeficiency Virus Infection

Macaques by Plant-Derived HIV Broadly Neutralizing Antibodies: a Model for Passive Immunotherapy 585 during Breastfeeding

Broadly neutralizing antibodies 587 targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge

Trispecific broadly neutralizing HIV 590 antibodies mediate potent SHIV protection in macaques

Infant 592 transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to paired 593 maternal plasma

The genetic bottleneck in 595 vertical transmission of subtype C HIV-1 is not driven by selection of especially neutralization-resistant 596 virus from the maternal viral population

Neutralization 598 escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant

Role of maternal autologous 601 neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape 602 variants

The breadth 607 and potency of passively acquired human immunodeficiency virus type 1-specific neutralizing antibodies 608 do not correlate with the risk of infant infection

Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies

Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced Transmission and Infant 614 Morbidity

Neutralizing antibodies generated during natural 616 HIV-1 infection: good news for an HIV-1 vaccine

Profiling the specificity of 618 neutralizing antibodies in a large panel of plasmas from patients chronically infected with human 619 immunodeficiency virus type 1 subtypes B and C

Frequency and 621 phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-622 neutralizing antibodies

Analysis of neutralization 624 specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals

Factors associated 627 with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus 628 type 1 infection

Human immunodeficiency virus 630 type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a 631 high-throughput neutralization assay together with an analytical selection algorithm

Prevalence of broadly 634 neutralizing antibody responses during chronic HIV-1 infection

Antibody neutralization and escape by 636 HIV-1

Temporal analysis of HIV envelope sequence 638 evolution and antibody escape in a subtype A-infected individual with a broad neutralizing antibody 639 response

Comprehensive Mapping of HIV-1 Escape from 641 a Broadly Neutralizing Antibody

Co-evolution of a broadly neutralizing 643 HIV-1 antibody and founder virus

Evolution of an HIV 645 glycan-dependent broadly neutralizing antibody epitope through immune escape

Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and function to 649 that of nontransmitted breast milk variants

Breast milk and in 651 utero transmission of HIV-1 select for envelope variants with unique molecular signatures

Short 654 communication: HIV type 1 subtype C variants transmitted through the bottleneck of breastfeeding are 655 sensitive to new generation broadly neutralizing antibodies directed against quaternary and CD4-binding 656 site epitopes

HIV-1 maternal and infant variants show 658 similar sensitivity to broadly neutralizing antibodies, but sensitivity varies by subtype

Maternal Broadly 661 Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV 662 Variants

Origin and 664 Evolution of HIV-1 in Breast Milk Determined by Single-Genome Amplification and Sequencing

Restricted isotype, 667 distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in 668 colostrum compared with those in blood of HIV-1-infected, lactating African women

Maternal or 671 Infant Antiretroviral Drugs to Reduce HIV-1 Transmission

Optimal Combinations 674 of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection. PLoS 675 Pathog

Optimization and 677 validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1

Neutralizing antibody vaccine for 680 pandemic and pre-emergent coronaviruses

SeaView Version 4: A Multiplatform Graphical User Interface for 682

Molecular Evolutionary Genetics Analysis 684 across Computing Platforms

NEP: web server for epitope prediction based on 686 antibody neutralization of viral strains with diverse sequences

Focused Evolution of HIV-1 Neutralizing 689

Structural Basis for Broad and Potent 691 Neutralization of HIV-1 by Antibody VRC01

Human Immunodeficiency Virus Type 1 V1-V2 Envelope 693 Loop Sequences Expand and Add Glycosylation Sites over the Course of Infection

HIV-1 Coreceptor Usage and 696

Variable Loop Contact Impact V3 Loop Broadly Neutralizing Antibody Susceptibility

HIV-1 Neutralizing Antibody 698 Signatures and Application to Epitope-Targeted Vaccine Design

The HIV-1 transmission bottleneck

Subtle alteration of residues including N-linked glycans in V2 702 loop modulate HIV-1 neutralization by PG9 and PG16 monoclonal antibodies

Mutations that confer 707 resistance to broadly-neutralizing antibodies define HIV-1 variants of transmitting mothers from that of 708 non-transmitting mothers

An Antigenic Atlas of HIV-1 Escape from 710 Broadly Neutralizing Antibodies Distinguishes Functional and Structural Epitopes

Genotypes in Breast Milk Does Not Account for the Population Transmission Genetic Bottleneck That 714 Occurs following Transmission

Origin and 716 evolution of HIV-1 in breast milk determined by single-genome amplification and sequencing

V2 V3 347 196 2315.g7i_V1 CTKVNGNVTY ANGTVANDN